Evidence map›Paper›PMID 27077338›Full record

ArticleAmerican journal of public health2016

New Product Marketing Blurs the Line Between Nicotine Replacement Therapy and Smokeless Tobacco Products.

Ganna Kostygina, Lucinda England, Pamela Ling

Open access · greenAbstract read
In one paragraph

Article in American journal of public health, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. The Potential Impact of Oral Nicotine Pouches on Public Health: A Scoping Review.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Review
  11. Article
  12. Administration ofFrontiers in behavioral neuroscience · 2020
    Article
  13. Article
  14. Article
  15. Article
  16. Zonnic®: a new player in an old field.Substance abuse treatment, prevention, and policy · 2017
    Review
  17. Review
  18. Smoking Harm Reduction.American journal of public health · 2016
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ganna KostyginaAt the time of study, Ganna Kostygina and Pamela Ling were with the Center for Tobacco Control Research and Education and the Division of General Internal Medicine, Department of Medicine, University of California, San Francisco. Lucinda England was with the Centers for Disease Control and Prevention, Atlanta, GA.
Lucinda EnglandAt the time of study, Ganna Kostygina and Pamela Ling were with the Center for Tobacco Control Research and Education and the Division of General Internal Medicine, Department of Medicine, University of California, San Francisco. Lucinda England was with the Centers for Disease Control and Prevention, Atlanta, GA.
Pamela LingAt the time of study, Ganna Kostygina and Pamela Ling were with the Center for Tobacco Control Research and Education and the Division of General Internal Medicine, Department of Medicine, University of California, San Francisco. Lucinda England was with the Centers for Disease Control and Prevention, Atlanta, GA.
The Centers · US

Funding

Understanding Smokeless Tobacco MarketingR01CA141661 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LING, PAMELA MAY · 2009 to 2019
$5.4M
NCI NIH HHS R01 CA141661
6 · The paper itself

Abstract

Tobacco companies have begun to acquire pharmaceutical subsidiaries and recently started to market nicotine replacement therapies, such as Zonnic nicotine gum, in convenience stores. Conversely, tobacco companies are producing tobacco products such as tobacco chewing gum and lozenges that resemble pharmaceutical nicotine replacement products, including a nicotine pouch product that resembles snus pouches. This convergence of nicotine and tobacco product marketing has implications for regulation and tobacco cessation.

Indexed as

AdvertisingHumansMarketingSmoking CessationTobacco, SmokelessTobacco Use Cessation Devices

Identifiers

PMID27077338
PMCPMC4984756
OpenAlexW2337326101

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.